ESTRO 2024 - Abstract Book

S2855

Interdisciplinary - Health economics & health services research

ESTRO 2024

Conclusion:

More sophisticated adaptive strategies than the current trigger-based offline strategy offer the potential to reduce toxicity risks without compromising target coverage. Automation plays a key role in the feasibility of the proposed adaptive strategies. Daily dose refinement emerges as an effective strategy to improve toxicity risks, although demanding considerable additional workload and fraction time. This may be substantially reduced by plan library approaches or weekly offline replanning.

Keywords: adaptive IMPT, cost-benefit, workload

References:

1. Van De Water, S., et al., The price of robustness; impact of worst-case optimization on organ-at-risk dose and complication probability in intensity-modulated proton therapy for oropharyngeal cancer patients. Radiotherapy and Oncology, 2016. 120(1): p. 56-62.

2. Oud, M., et al., An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer. Radiotherapy and Oncology, 2022. 176: p. 68-75.

3. Sanchez, R., Technology readiness assessment guide. United States Department of Energy: Washington, DC, USA, 2011: p. 73.

4.

Bastogne, T., IQbD: A Technological Readiness Level-Indexed Quality-by-Design Paradigm for Medical

Device Engineering. Journal of Medical Devices, 2022. 16(2): p. 021008.

5. Protonentherapie, L.P.P., Landelijk Indicatie Protocol Protonen Therapie Hoofd-halstumoren. 2019.

2684

Digital Poster

Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: a decision analysis

Nataniel H Lester-Coll 1 , James B Yu 2

1 University of Vermont College of Medicine, Radiation Oncology, Burlington, USA. 2 Connecticut Radiation Oncology, Radiation Oncology, Hartford, USA

Purpose/Objective:

Randomized trials comparing trimodality bladder preservation with radical cystectomy for muscle-invasive bladder cancer (MIBC) are lacking. A multi-institutional study showed similar overall survival, cancer-specific survival and disease-free survival between trimodality therapy and radical cystectomy in selected patients with MIBC (1). Health related quality of life has also been studied in survivors of MIBC, with good long-term outcomes reported in both